Published in Urology on August 01, 2003
Muscarinic receptors in the bladder: from basic research to therapeutics. Br J Pharmacol (2006) 1.44
Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach. PLoS One (2011) 1.16
Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials. World J Urol (2005) 1.10
Pharmacotherapy of overactive bladder in adults: a review of efficacy, tolerability, and quality of life. Res Rep Urol (2013) 1.06
Overactive bladder drugs and constipation: a meta-analysis of randomized, placebo-controlled trials. Dig Dis Sci (2010) 1.05
α1-Adrenoceptors and muscarinic receptors in voiding function - binding characteristics of therapeutic agents in relation to the pharmacokinetics. Br J Clin Pharmacol (2011) 0.93
Pharmacologic management of overactive bladder. Clin Interv Aging (2007) 0.88
The puzzle of overactive bladder: controversies, inconsistencies, and insights. Int Urogynecol J Pelvic Floor Dysfunct (2006) 0.87
The evolution of transdermal/topical overactive bladder therapy and its benefits over oral therapy. Rev Urol (2009) 0.84
The effect of mirabegron on patient-related outcomes in patients with overactive bladder: the results of post hoc correlation and responder analyses using pooled data from three randomized Phase III trials. Qual Life Res (2015) 0.84
Defining efficacy in the treatment of overactive bladder syndrome. Rev Urol (2009) 0.84
A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder. BMC Med Res Methodol (2009) 0.84
Management of overactive bladder syndrome. Postgrad Med J (2007) 0.82
Concomitant medications and possible side effects of antimuscarinic agents. Rev Urol (2008) 0.82
A comparative review of oxybutynin chloride formulations: pharmacokinetics and therapeutic efficacy in overactive bladder. Rev Urol (2010) 0.81
Mixed urinary incontinence: international urogynecological association research and development committee opinion. Int Urogynecol J (2014) 0.81
Management of overactive bladder with transdermal oxybutynin. Rev Urol (2006) 0.81
Addressing the need for a simpler algorithm for the management of women with urinary incontinence. MedGenMed (2005) 0.79
Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions. Int J Clin Pract (2007) 0.79
Behavioral intervention versus pharmacotherapy or their combinations in the management of overactive bladder dysfunction. Adv Urol (2009) 0.79
The safety and efficacy of tolterodine extended release in the treatment of overactive bladder in the elderly. Clin Interv Aging (2009) 0.78
Update on the management of overactive bladder: patient considerations and adherence. Open Access J Urol (2010) 0.78
Update on tolterodine extended-release for treatment of overactive bladder. Open Access J Urol (2010) 0.78
Will the evolution of overactive bladder delivery systems increase patient compliance? Rev Urol (2009) 0.78
Prevalence, management and outcomes of medically complex vulnerable elderly patients with urinary incontinence in the United States. Int J Clin Pract (2015) 0.78
Current trends in the evaluation and management of female urinary incontinence. CMAJ (2006) 0.77
The evolution of transdermal/ topical overactive bladder therapy and its benefits over oral therapy. Rev Obstet Gynecol (2009) 0.77
Management of urinary incontinence. P T (2012) 0.76
Transdermal oxybutynin in the treatment of overactive bladder. Clin Interv Aging (2006) 0.76
Clinical utility of transdermal delivery of oxybutynin gel via a metered-dose pump in the management of overactive bladder. Res Rep Urol (2012) 0.75
[Not Available]. Can Urol Assoc J (2014) 0.75
An update on the use of transdermal oxybutynin in the management of overactive bladder disorder. Ther Adv Urol (2016) 0.75
Oxybutynin topical gel in the treatment of overactive bladder. Open Access J Urol (2010) 0.75
Characterization of bladder selectivity of antimuscarinic agents on the basis of in vivo drug-receptor binding. Int Neurourol J (2012) 0.75
Oxybutynin: an overview of the available formulations. Ther Clin Risk Manag (2006) 0.75
Treatment of the overactive bladder: where we stand in 2003. Rev Urol (2003) 0.75
Comparison between ketamine and hyoscine for the management of postoperative catheter-related bladder discomfort: A randomized controlled double-blind study. J Anaesthesiol Clin Pharmacol (2017) 0.75
Overactive bladder - 18 years - Part II. Int Braz J Urol (2016) 0.75
Development of oxybutynin chloride topical gel for overactive bladder. Open Access J Urol (2011) 0.75
Transdermal therapy for overactive bladder: present and future. Rev Urol (2003) 0.75
Antimuscarinic therapy for the treatment of mixed incontinence. Rev Urol (2003) 0.75
Patient perspectives in the management of overactive bladder, focus on transdermal oxybutynin. Patient Prefer Adherence (2008) 0.75
Trospium chloride extended release is effective and well tolerated in women with overactive bladder syndrome. Int Urogynecol J Pelvic Floor Dysfunct (2009) 0.75
Patient-reported most bothersome symptoms in OAB: post hoc analysis of data from a large, open-label trial of solifenacin. Int Urogynecol J Pelvic Floor Dysfunct (2009) 0.75
Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies. Neurourol Urodyn (2002) 8.01
An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J (2009) 7.12
An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn (2010) 5.48
Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol (2005) 3.22
Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc (2003) 2.75
Duloxetine versus placebo in the treatment of stress urinary incontinence. Am J Obstet Gynecol (2002) 2.16
Foreign-body granuloma after injection of calcium hydroxylapatite for type III stress urinary incontinence. Obstet Gynecol (2011) 1.75
Botulinum toxin A in the overactive bladder: current status and future directions. BJU Int (2007) 1.69
Two unusual presentations of bladder diverticula. Obstet Gynecol (2011) 1.67
Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: a 9-month, open-label extension study. Urology (2009) 1.67
Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. J Urol (2003) 1.56
The use of intraoperative cystoscopy in major vaginal and urogynecologic surgeries. Am J Obstet Gynecol (2002) 1.56
Incidence of pubic osteomyelitis after bladder neck suspension using bone anchors. Urology (2004) 1.56
Can pelvic floor injury secondary to delivery be prevented? Int Urogynecol J (2011) 1.46
Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clin Proc (2003) 1.43
Histologic characterization of vaginal vs. abdominal surgical wound healing in a rabbit model. Wound Repair Regen (2007) 1.39
Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol (2002) 1.32
Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol (2007) 1.27
Are there predictors of outcome following rectovaginal fistula repair? Dis Colon Rectum (2010) 1.24
Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT). Clin Ther (2006) 1.23
Perceptions and behaviours of women with bladder control problems. Fam Pract (2006) 1.22
Outcome measures and definition of cure in female stress urinary incontinence surgery: a survey of recent publications. Int Urogynecol J (2010) 1.16
Delivery mode is a major environmental determinant of stress urinary incontinence: results of the Evanston-Northwestern Twin Sisters Study. Am J Obstet Gynecol (2005) 1.16
Mixed urinary incontinence symptoms: urodynamic findings, incontinence severity, and treatment response. Obstet Gynecol (2003) 1.15
Is transobturator tape as effective as tension-free vaginal tape in patients with borderline maximum urethral closure pressure? Am J Obstet Gynecol (2006) 1.14
Repeat versus primary slings in patients with intrinsic sphincter deficiency. Int Urogynecol J (2012) 1.11
Detrusor overactivity and urge urinary incontinence following trans obturator versus midurethral slings. Neurourol Urodyn (2007) 1.11
Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study. J Urol (2009) 1.11
Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials. World J Urol (2005) 1.10
Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia. J Urol (2004) 1.09
Extrasphincteric perianal fistulae after sacrospinous fixation for apical prolapse. Obstet Gynecol (2011) 1.08
Risk factors for female anal incontinence: new insight through the Evanston-Northwestern twin sisters study. Obstet Gynecol (2005) 1.08
A prospective randomized trial using solvent dehydrated fascia lata for the prevention of recurrent anterior vaginal wall prolapse. Am J Obstet Gynecol (2005) 1.07
Predictors of persistent detrusor overactivity after transvaginal sling procedures. Am J Obstet Gynecol (2008) 1.07
Effect of parity on sexual function: an identical twin study. Obstet Gynecol (2006) 1.07
Pharmacokinetics and metabolism of transdermal oxybutynin: in vitro and in vivo performance of a novel delivery system. Pharm Res (2003) 1.06
Diagnosis of interstitial cystitis/ painful bladder syndrome in patients with overactive bladder symptoms. Rev Urol (2007) 1.02
Transdermal delivery of drugs for urologic applications: basic principles and applications. Urology (2006) 1.01
Air-charged and microtransducer urodynamic catheters in the evaluation of urethral function. Int Urogynecol J Pelvic Floor Dysfunct (2004) 0.98
Levator ani deficiency and pelvic organ prolapse severity. Obstet Gynecol (2013) 0.98
Histopathologic changes of porcine dermis xenografts for transvaginal suburethral slings. Am J Obstet Gynecol (2005) 0.97
Functional disorders: rectocele. Clin Colon Rectal Surg (2008) 0.96
Site-specific rectocele repair compared with standard posterior colporrhaphy. Obstet Gynecol (2005) 0.96
Obliterative LeFort colpocleisis in a large group of elderly women. Obstet Gynecol (2013) 0.96
Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double-blind, placebo-controlled trial. Neurourol Urodyn (2012) 0.96
Nocturia: etiology, diagnosis, and treatment. Neurourol Urodyn (2008) 0.93
Urinary incontinence among mothers of multiples: the protective effect of cesarean delivery. Am J Obstet Gynecol (2003) 0.92
Safety and effectiveness of Colpexin Sphere in the treatment of pelvic organ prolapse. Int Urogynecol J Pelvic Floor Dysfunct (2005) 0.91
Impact of hysterectomy on stress urinary incontinence: an identical twin study. Am J Obstet Gynecol (2008) 0.90
Extended-release trospium chloride improves quality of life in overactive bladder. Value Health (2009) 0.90
Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study. Urology (2008) 0.89
Do alterations in vaginal dimensions after reconstructive pelvic surgeries affect the risk for dyspareunia? Am J Obstet Gynecol (2005) 0.89
Validation of a global pelvic floor symptom bother questionnaire. Int Urogynecol J (2010) 0.88
Transdermal drug delivery treatment for overactive bladder. Int Braz J Urol (2006) 0.88
Time to initiation of pentosan polysulfate sodium treatment after interstitial cystitis diagnosis: effect on symptom improvement. Urology (2008) 0.88
Pelvic floor dysfunction in morbidly obese women: pilot study. Obes Res (2004) 0.87
Initial experience with a new method for the dynamic assessment of pelvic floor function in women: the Kolpexin Pull Test. Int Urogynecol J Pelvic Floor Dysfunct (2004) 0.87
Arcus-anchored acellular dermal graft compared to anterior colporrhaphy for stage II cystoceles and beyond. Int Urogynecol J Pelvic Floor Dysfunct (2009) 0.86
Anterior repair with or without collagen matrix reinforcement: a randomized controlled trial. Obstet Gynecol (2009) 0.85
Primary versus recurrent prolapse surgery: differences in outcomes. Int Urogynecol J (2009) 0.85
TVT versus SPARC: comparison of outcomes for two midurethral tape procedures. Int Urogynecol J Pelvic Floor Dysfunct (2005) 0.85
Pathophysiology of the overactive bladder. Clin Obstet Gynecol (2002) 0.85
An inelastic retropubic suburethral sling in women with intrinsic sphincter deficiency. Int Urogynecol J (2012) 0.85
Treatment options for patients with suboptimal response to surgery for stress urinary incontinence. Curr Med Res Opin (2007) 0.84
Measuring the success of combined intravesical dimethyl sulfoxide and triamcinolone for treatment of bladder pain syndrome/interstitial cystitis. Int Urogynecol J (2012) 0.84
Prevalence of anal incontinence among mothers of multiples and analysis of risk factors. Am J Obstet Gynecol (2003) 0.84
The PISQ-IR: considerations in scale scoring and development. Int Urogynecol J (2013) 0.84
A Valid Form of the PISQ-12, the PISQ-9, for Use in Comparative Studies of Women With and Without Pelvic Organ Prolapse and/or Urinary Incontinence. Female Pelvic Med Reconstr Surg (2010) 0.83
Fesoterodine in patients with overactive bladder syndrome: can the severity of baseline urgency urinary incontinence predict dosing requirement? BJU Int (2010) 0.83
Transvaginal placement of surgical mesh for pelvic organ prolapse: more FDA concerns--positive reactions are possible. Int Urogynecol J (2011) 0.83
Effect of bilateral oophorectomy on wound healing of the rabbit vagina. Fertil Steril (2010) 0.83
Detrusor overactivity and urge urinary incontinence [corrected] following midurethral versus bladder sling procedures. Am J Obstet Gynecol (2005) 0.83
Biologic grafted repair of urethrovaginal fistula and concomitant synthetic sling. Int Urogynecol J (2013) 0.83
Vaginal laxity: a poorly understood quality of life problem; a survey of physician members of the International Urogynecological Association (IUGA). Int Urogynecol J (2012) 0.82
The development of pelvic organ prolapse following isolated Burch retropubic urethropexy. Int Urogynecol J Pelvic Floor Dysfunct (2003) 0.82
Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: a subanalysis of data from the OPERA trial. Am J Obstet Gynecol (2005) 0.82
Management of incontinence for family practice physicians. Am J Med (2006) 0.81
Expression of platelet-derived growth factor-B mRNA during vaginal vs. dermal incisional wound healing in the rabbit. Eur J Obstet Gynecol Reprod Biol (2012) 0.81
Bladder-health diaries: an assessment of 3-day vs 7-day entries. BJU Int (2005) 0.81
Urge incontinence: estimating environmental and obstetrical risk factors using an identical twin study. Int Urogynecol J (2010) 0.81
Pharmacokinetics of oxybutynin chloride topical gel: effects of application site, baths, sunscreen and person-to-person transference. Clin Drug Investig (2011) 0.81
Long-term efficacy and tolerability of once-yearly histrelin acetate subcutaneous implant in patients with advanced prostate cancer. BJU Int (2011) 0.81
Suprapubic-vaginocutaneous fistula 18 years after a bladder-neck suspension. Obstet Gynecol (2005) 0.81